Compare BEDU & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BEDU | CGTX |
|---|---|---|
| Founded | 1994 | 2007 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.0M | 158.8M |
| IPO Year | 2017 | 2021 |
| Metric | BEDU | CGTX |
|---|---|---|
| Price | $2.19 | $1.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.88 |
| AVG Volume (30 Days) | 4.7K | ★ 977.9K |
| Earning Date | 01-23-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $224,321,752.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.35 | $0.22 |
| 52 Week High | $2.28 | $3.83 |
| Indicator | BEDU | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 57.57 | 54.36 |
| Support Level | $2.14 | $1.58 |
| Resistance Level | $2.22 | $1.81 |
| Average True Range (ATR) | 0.03 | 0.13 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 43.75 | 82.30 |
Bright Scholar Education Holdings Ltd operates as an education service provider. It is engaged in the provision of education services, including complementary education services, operation services for domestic schools, and education programs and services including independent schools and colleges in United Kingdom and the United States. It nearly eight overseas school located in the United Kingdom and the United States. It has three reportable segments, including Overseas Schools, Complementary Education Services, and K-12 Operation Services. Key revenue is generated from Overseas Schools. From a geographical perspective: Key revenue is generated from China following UK, U.S., Canada and Singapore.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.